Skip to main content

VAPOR 2 Study Pivotal Study Clinical Protocol/Frye/IUGUP23019

Basic Study Information

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Thomas Frye

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search